Bracco inks deal with Marillion

Italian contrast firm Bracco Imaging of Milan and oncology pharmaceutical developer Marillion Pharmaceuticals have signed a license agreement.

Under the deal, Exton, PA-based Marillion gains exclusive worldwide rights to complete clinical development and commercialization of Bracco's 177Lu-AMBA radiotherapeutic for the treatment of hormone-resistant prostate and advanced metastatic breast cancers.

Related Reading

Road to RSNA, MRI, Bracco Diagnostics, October 31, 2008

Road to RSNA, CT, Bracco Diagnostics, October 29, 2008

Lantheus to license Bracco's CardioGen PET tracer, September 24, 2008

Bracco, Novation ink supply deal, September 3, 2008

Bracco touts contrast study results, August 5, 2008

Copyright © 2008

Page 1 of 1235
Next Page